Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09JFY
|
|||
| Former ID |
DCL000519
|
|||
| Drug Name |
Dutasteride + tamsulosin
|
|||
| Synonyms |
Jalyn; Dutasteride / tamsulosin; Tamsulosin / Dutasteride; Dutasteride mixture with tamsulosin
Click to Show/Hide
|
|||
| Drug Type |
Combination drug (small molecular drug)
|
|||
| Indication | Benign prostatic hyperplasia [ICD-11: GA90; ICD-10: N40] | Phase 3 | [1] | |
| Prostate cancer [ICD-11: 2C82.0] | Phase 3 | [1] | ||
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C47H58F6N4O7S
|
|||
| Canonical SMILES |
CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N.CC12CCC3C(C1CCC2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CCC5C3(C=CC(=O)N5)C
|
|||
| InChI |
1S/C27H30F6N2O2.C20H28N2O5S/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33;1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36);5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-,16-,17-,19+,21+,24-,25+;15-/m01/s1
|
|||
| InChIKey |
SHHCJPKACHSWFP-NMXGMQNUSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-1A (ADRA1A) | Target Info | Antagonist | [2] |
| Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| AMPK signaling pathway | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Vascular smooth muscle contraction | ||||
| Salivary secretion | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Reactome | Adrenoceptors | |||
| G alpha (q) signalling events | ||||
| G alpha (12/13) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| AMPK Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00090103) Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.